Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center

Overview of attention for article published in Experimental Hematology & Oncology, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,575 followers.

RT @Lymphoma_Papers: Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-ce…

17 Sep 2022

Reply Repost Favourite

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center #lymphoma #lymsm https://t.co/8bolp2VkKi

17 Sep 2022

Reply Repost Favourite

New article: Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center https://t.co/2j1BPRe7QT #DLBCL #lymsm #hematology https://t.co/o5W2tsG0Jm

17 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.